AstraZeneca

News

Risk of brain clots higher with COVID than vaccine, study su...

A study has suggested that the risk of getting a serious brain clot is eight to 10 times higher in people with COVID-19 than those who get a vaccine.

News

Czech Republic swoops for Denmark's 2.4m unwanted AZ COVID s...

The Czech Republic wants to buy around 2.4 million doses of the AstraZeneca/Oxford University vaccine ditched by Denmark, which has said it will stop using it because of concerns about rare

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ aims at Pfizer, GSK with potential new PARP cancer drug

AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer.

News

AstraZeneca's Farxiga fails phase 3 COVID-19 test

Hope that AstraZeneca's diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed after the drug failed to make an impact in a phase 3 trial.

News

UK will offer under-30s alternative to AZ's COVID jab

The UK drugs regulator has said people aged under 30 should be offered an alternative to the AstraZeneca COVID-19 vaccine, because of evidence linking it to rare blood clots.

News

Paediatric trial of AZ COVID jab 'halted as a precaution'

Oxford University has suspended a clinical trial of its AstraZeneca-partnered COVID-19 vaccine in children and adolescents while a possible link to rare cases of blood clotting is investiga

Risk of brain clots higher with COVID than vaccine, study su...

Czech Republic swoops for Denmark's 2.4m unwanted AZ COVID s...

AZ aims at Pfizer, GSK with potential new PARP cancer drug

AstraZeneca's Farxiga fails phase 3 COVID-19 test

UK will offer under-30s alternative to AZ's COVID jab

Paediatric trial of AZ COVID jab 'halted as a precaution'

US launches probe of German 'underpayment' for medicines

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks